Gene Therapies for Cardiomyopathies Market to Experience Rapid Expansion by 2034: DelveInsight

The gene therapies for cardiomyopathies market is expected to grow rapidly due to advancements in genomic medicine, targeted treatments for inherited and acquired cardiac disorders, and emerging candidates such as LX2020 and LX2006 from Lexeo Therapeutics and AB-1002 from AskBio. The US market size is expected to grow significantly by 2034, with leading companies developing new therapies such as Lexeo Therapeutics, AskBio, Tenaya Therapeutics, and Rocket Pharmaceuticals. Promising gene therapies for cardiomyopathies in clinical trials include LX2020, LX2022, LX2006, AB-1002, TN-201, RP-A701, and RP-A501.